Employee Benefit News January 21, 2025
Dr. Nancy Klotz

Gene therapy, a revolutionary approach to treating disease by modifying a person’s genes, is one of the most transformative developments in healthcare today. In certain cases, it can offer a cure for an otherwise deadly or debilitating disease, but it’s also one of the most expensive treatments available. A recent story in the New York Times about gene therapy for sickle-cell trait lays bare the tough decision for benefits administrators — paying for this treatment is extraordinarily expensive, the therapy can be difficult for patients to endure and there are no guarantees of success.

Though the number of people in the U.S. who have received gene therapy is still relatively small, by 2034, more than a million people will...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Employer, Pharma / Biotech
Are third-party telehealth prescriptions of GLP-1s safe?
Study sheds new light on brain evolution
Merck Is Embracing AI, But ‘We Always Have a Human in the Loop,’ Exec Says
Do GLP-1s curb alcohol consumption?
The ‘Hidden Gem’ Healthtech Areas VCs Have Their Eye On

Share This Article